Literature DB >> 22425565

Footprint-based identification of viral entry inhibitors targeting HIVgp41.

Patrick M Holden1, Harmeet Kaur, Rashi Goyal, Miriam Gochin, Robert C Rizzo.   

Abstract

A targeted virtual screen to the N-helix hydrophobic pocket on HIVgp41 was performed using DOCK followed by re-ranking with a new footprint-based scoring function which employed native gp41 C-helix residues as a reference. Of ca. 500,000 small molecules screened, 115 were purchased, and 7 hits were identified with favorable binding (K(i)), cell-cell fusion (IC(50)), and cytotoxicity (CC(50)) profiles. Three of the seven active compounds would not have been discovered without the use of the footprints, demonstrating the utility of the method for structure-based design when a known reference compound or substrate is available.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425565      PMCID: PMC3321075          DOI: 10.1016/j.bmcl.2012.02.017

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

Review 1.  Resistance to enfuvirtide, the first HIV fusion inhibitor.

Authors:  Michael L Greenberg; Nick Cammack
Journal:  J Antimicrob Chemother       Date:  2004-07-01       Impact factor: 5.790

2.  Docking validation resources: protein family and ligand flexibility experiments.

Authors:  Sudipto Mukherjee; Trent E Balius; Robert C Rizzo
Journal:  J Chem Inf Model       Date:  2010-10-29       Impact factor: 4.956

3.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

4.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

5.  A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.

Authors:  Lifeng Cai; Miriam Gochin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

6.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

7.  Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.

Authors:  Guangyan Zhou; Dong Wu; Beth Snyder; Roger G Ptak; Harmeet Kaur; Miriam Gochin
Journal:  J Med Chem       Date:  2011-10-03       Impact factor: 7.446

8.  Origins of resistance to the HIVgp41 viral entry inhibitor T20.

Authors:  Brian E McGillick; Trent E Balius; Sudipto Mukherjee; Robert C Rizzo
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

9.  Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Authors:  M Mink; S M Mosier; S Janumpalli; D Davison; L Jin; T Melby; P Sista; J Erickson; D Lambert; S A Stanfield-Oakley; M Salgo; N Cammack; T Matthews; M L Greenberg
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

10.  Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment.

Authors:  Bentley Strockbine; Robert C Rizzo
Journal:  Proteins       Date:  2007-05-15
View more
  16 in total

1.  Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41.

Authors:  Trent E Balius; William J Allen; Sudipto Mukherjee; Robert C Rizzo
Journal:  J Comput Chem       Date:  2013-02-22       Impact factor: 3.376

2.  Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets.

Authors:  William J Allen; Brian C Fochtman; Trent E Balius; Robert C Rizzo
Journal:  J Comput Chem       Date:  2017-09-22       Impact factor: 3.376

3.  Strategies for lead discovery: application of footprint similarity targeting HIVgp41.

Authors:  Patrick M Holden; William J Allen; Miriam Gochin; Robert C Rizzo
Journal:  Bioorg Med Chem       Date:  2013-10-26       Impact factor: 3.641

4.  Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation.

Authors:  William J Allen; Hyun Ah Yi; Miriam Gochin; Amy Jacobs; Robert C Rizzo
Journal:  Bioorg Med Chem Lett       Date:  2015-04-28       Impact factor: 2.823

5.  DOCK 6: Impact of new features and current docking performance.

Authors:  William J Allen; Trent E Balius; Sudipto Mukherjee; Scott R Brozell; Demetri T Moustakas; P Therese Lang; David A Case; Irwin D Kuntz; Robert C Rizzo
Journal:  J Comput Chem       Date:  2015-06-05       Impact factor: 3.376

Review 6.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

Review 7.  Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Authors:  Lu Lu; Fei Yu; Lifeng Cai; Asim K Debnath; Shibo Jiang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

8.  Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs.

Authors:  William T Berger; Brian P Ralph; Martin Kaczocha; Jing Sun; Trent E Balius; Robert C Rizzo; Samir Haj-Dahmane; Iwao Ojima; Dale G Deutsch
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 9.  Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.

Authors:  Fei Yu; Lu Lu; Lanying Du; Xiaojie Zhu; Asim K Debnath; Shibo Jiang
Journal:  Viruses       Date:  2013-01-11       Impact factor: 5.048

10.  Computer-Aided Approaches for Targeting HIVgp41.

Authors:  William J Allen; Robert C Rizzo
Journal:  Biology (Basel)       Date:  2012-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.